

Elmore et al
Appl. No. 08/981,087
August 19, 2003

COPY**IN THE CLAIMS:**

Amend the claims as follows.

Claims 1-4 (Canceled).

5. (Allowed) An isolated polypeptide comprising a sequence of no more than 700 consecutive amino acids of a type F botulinum toxin sequence, which comprises a sequence of amino acids selected from the group consisting of:

- (a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO: 1)
- (b) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO: 3), and;
- (c) amino acids 1136-1278 of a type F botulinum toxin (SEQ ID NO: 4).

6. (Allowed) An isolated polypeptide comprising a dimer of a polypeptide comprising no more than 700 consecutive amino acids of a type F botulinum toxin sequence, which comprises a sequence selected from the group consisting of:

- (a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO: 1)
- (b) amino acids 848-991 of a type F botulinum toxin (SEQ ID NO: 2).
- (c) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO: 3), and
- (d) amino acids 1136-1278 of a type F botulinum toxin (SEQ ID NO: 4).

7. (Currently) A polypeptide composition comprising:

- (1) an isolated polypeptide according to claim 5; and
- (2) an isolated polypeptide that facilitates or enhances purification polypeptide of the polypeptide of (1).

Elmore et al
Appl. No. 08/981,087
August 19, 2003

COPY

⁴8. (Currently Amended) An isolated fusion protein comprising a sequence of amino acids selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, ~~SEQ ID~~ and SEQ ID NO:4, fused to a polypeptide that facilitates or enhances purification.

⁴9. (Previously Amended) A fusion protein according to Claim 8 wherein said polypeptide that facilitates or enhances purification is a polypeptide that binds a chromatography column.

⁵10. (Previously Amended) A fusion protein according to Claim 9 wherein said chromatography column is an affinity chromatography column.

⁴11. (Previously Amended) A fusion protein according to Claim 8 which comprises SEQ ID NO:1 fused to a purification moiety.

⁴12. (Allowed) A vaccine comprising a pharmaceutically acceptable carrier and a polypeptide comprising no more than 700 consecutive amino acids of a type F botulinum toxin sequence, which comprises a sequence selected from the group consisting of:

- (a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO:1),
- (b) amino acids 848-991 of a type F botulinum toxin (SEQ ID NO:2),
- (c) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO:3),

Elmore et al
Appl. No. 08/981,087
August 19, 2003

COPY

and

(d) amino acids 1136-1278 of a type F botulinum toxin (SEQ ID NO:4).

⁹13. (Allowed) A recombinant DNA encoding a polypeptide according to claim ¹5.

¹⁰14. (Previously Amended) A method of producing a polypeptide according to claim ⁴8 comprising the steps of:

(a) expressing in a host cell a DNA encoding a fusion protein according to claim

⁴8;

(b) obtaining from said host cell an extract comprising the fusion protein, and

(c) purifying the fusion protein using a chromatography column.

¹¹15. (Previously Amended) A method according to claim ¹⁰14 wherein the fusion protein is removed from the column by elution with a substrate.

¹²16. (Previously Amended) A method according to Claim ¹⁰14 further comprising cleaving the fusion protein and retaining the toxin fragment.

¹³17. (Currently Amended) A method of making a pharmaceutical composition comprising:

(a) expressing in a host cell a DNA fragment encoding a fusion protein according to claim ⁴8;

(b) obtaining from said host cell an extract comprising the fusion protein,

Elmore et al
Appl. No. 08/981,087
August 19, 2003

COPY

- (c) purifying the fusion protein using a chromatography column, and
- (d) incorporating the purified fusion protein into a pharmaceutical composition.

¹⁴~~18~~. (Currently Amended) A method according to Claim ¹³~~17~~ wherein said the
fusion protein comprises a purification moiety that binds to an affinity chromatography
column.

¹⁴~~19~~. (Previously Amended) A pharmaceutical composition comprising a fusion
protein according to claim ⁴~~8~~, and
a pharmaceutically acceptable carrier.

Claim 20 (Canceled).

¹⁶~~21~~. (Previously Amended) A pharmaceutical composition according to Claim ¹⁵~~19~~
wherein the fusion protein comprises a polypeptide that binds to an affinity
chromatography column.

Claims 22-24 (Canceled).

¹⁷~~25~~. (Previously Amended) A recombinant DNA encoding a fusion protein
according to claim ⁴~~8~~.

Claims 26-29 (Canceled).

Elmore et al
Appl. No. 08/981,087
August 19, 2003

COPY

¹⁸30. (Currently Amended) The fusion protein of claim ⁴8 wherein the sequence of amino acids is (1) ~~is at least one amino acid sequence~~ selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.

Claim 31 (Canceled).

¹⁹32. (Allowed) A method of producing antibodies in a mammal against botulinum toxin, comprising administering to said mammal a vaccine according to claim ⁸12.

⁷⁰38. (Previously Amended) A method of producing antibodies in a mammal against botulinum toxin, comprising administering to said mammal a composition of claim ¹⁵19.

²¹34. (Allowed) A method of vaccinating a mammal against a botulinum toxin, said method comprising administering to said mammal a polypeptide comprising no more than 700 consecutive amino acids of a type F botulinum toxin sequence, which includes a sequence selected from the group consisting of:

- (a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO:1)
- (b) amino acids 848-991 of a type F botulinum toxin (SEQ ID NO:2)
- (c) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO:3),

and;

- (d) amino acids 1136-1278 of a type F botulinum toxin (SEQ ID NO:4).

Elmore et al
Appl. No. 08/981,087
August 19, 2003

COPY

²³~~35~~. (Allowed) A method according to claim ²¹~~34~~ wherein the said sequence is fused to a polypeptide that facilitates or enhances purification.

²³~~36~~. (Allowed) A method according to claim ²¹~~34~~ wherein said polypeptide comprises no more than 500 consecutive amino acids of a type F botulinum toxin sequence.

²⁴~~37~~. (Allowed) A method according to claim ²¹~~34~~ wherein said polypeptide consists of a sequence of amino acids selected from the group consisting of:

- (a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO:1)
- (b) amino acids 848-991 of a type F botulinum toxin (SEQ ID NO:2)
- (c) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO:3),

and;

(d) amino acids 1136-1278 of a type F botulinum toxin (SEQ ID NO:4), which sequence is optionally fused to a polypeptide that facilitates or enhances purification.

²⁵~~38~~. (Allowed) A method according to claim ²¹~~37~~ wherein the polypeptide consists of SEQ ID NO:1.

²⁶~~39~~. (Allowed) A method according to claim ²¹~~34~~ wherein the polypeptide is in the form of a dimer.

Elmore et al
Appl. No. 08/981,087
August 19, 2003

COPY

²⁷
~~40~~. (Allowed) An isolated polypeptide consisting of amino acids 848-991 of a type F botulinum toxin (SEQ ID NO:2) optionally fused to a polypeptide that facilitates or enhances purification.

²⁸
~~41~~. (Allowed) A recombinant DNA encoding a polypeptide according to claim ²⁷
~~40~~.